ECSP22073580A - Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano - Google Patents

Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano

Info

Publication number
ECSP22073580A
ECSP22073580A ECSENADI202273580A ECDI202273580A ECSP22073580A EC SP22073580 A ECSP22073580 A EC SP22073580A EC SENADI202273580 A ECSENADI202273580 A EC SENADI202273580A EC DI202273580 A ECDI202273580 A EC DI202273580A EC SP22073580 A ECSP22073580 A EC SP22073580A
Authority
EC
Ecuador
Prior art keywords
compound
formula
methods
antibacterial agent
oxazolidinone compound
Prior art date
Application number
ECSENADI202273580A
Other languages
English (en)
Inventor
Brendan Crowley
Lihu Yang
Lanying You
Takao Suzuki
Philippe Nantermet
Xin Yao
Original Assignee
Merck Sharp Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp Dohme Llc filed Critical Merck Sharp Dohme Llc
Publication of ECSP22073580A publication Critical patent/ECSP22073580A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere al compuesto de oxazolidinona de la Fórmula I: (I) y sales farmacéuticamente aceptables del mismo. La presente invención también se refiere a composiciones que contienen el compuesto de la Fórmula I. La invención también proporciona métodos para inhibir el crecimiento de células micobacterianas así como un método para tratar infecciones por micobacterias por Mycobacterium tuberculosis al administrar una cantidad terapéuticamente eficaz de la Fórmula I y/o una sal farmacéuticamente aceptable del mismo, o una composición que comprende tal compuesto y/o sal.
ECSENADI202273580A 2020-03-20 2022-09-19 Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano ECSP22073580A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/080359 WO2021184339A1 (en) 2020-03-20 2020-03-20 Oxazolidinone compound and methods of use thereof as an antibacterial agent

Publications (1)

Publication Number Publication Date
ECSP22073580A true ECSP22073580A (es) 2022-11-30

Family

ID=75478174

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202273580A ECSP22073580A (es) 2020-03-20 2022-09-19 Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano

Country Status (24)

Country Link
US (1) US12435077B2 (es)
EP (1) EP4121058B1 (es)
JP (1) JP7241984B2 (es)
KR (1) KR102824010B1 (es)
CN (1) CN115605208A (es)
AR (1) AR121598A1 (es)
AU (1) AU2021239937B2 (es)
BR (1) BR112022018674A2 (es)
CL (1) CL2022002511A1 (es)
CO (1) CO2022013595A2 (es)
CR (1) CR20220472A (es)
DK (1) DK4121058T3 (es)
EC (1) ECSP22073580A (es)
FI (1) FI4121058T3 (es)
GE (2) GEP20247641B (es)
IL (1) IL296401A (es)
LT (1) LT4121058T (es)
MA (1) MA59079B1 (es)
MX (1) MX2022011431A (es)
PE (1) PE20230002A1 (es)
PH (1) PH12022552495A1 (es)
TW (1) TWI799814B (es)
UA (1) UA130497C2 (es)
WO (2) WO2021184339A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3183397A1 (en) 2020-06-18 2021-12-23 Daryl C. Drummond Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
US20240390366A1 (en) * 2021-11-30 2024-11-28 Mannkind Corporation Formulation and method for topical treatment of mycobacterium ulcerans in buruli ulcers
EP4296674A1 (en) 2022-06-20 2023-12-27 Université Toulouse III - Paul Sabatier Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis
WO2024035618A1 (en) * 2022-08-10 2024-02-15 Merck Sharp & Dohme Llc Processes for preparing oxazolidinone compounds

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
EP0610265B1 (en) 1991-11-01 1996-12-27 PHARMACIA & UPJOHN COMPANY Substituted aryl- and heteroarylphenyloxazolidinones useful as antibacterial agents
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
DE69631347T2 (de) 1995-09-15 2004-10-07 Upjohn Co Aminoaryl oxazolidinone n-oxide
DK1114819T3 (da) 1996-04-11 2008-04-14 Pharmacia & Upjohn Co Llc Fremgangsmåde til fremstilling af oxazolidinoner
SK156499A3 (en) 1997-05-30 2000-06-12 Upjohn Co Oxazolidinone antibacterial agents having a thiocarbonyl functionality
US6255304B1 (en) 1997-05-30 2001-07-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
BR9910443A (pt) 1998-05-18 2001-01-02 Upjohn Co Aperfeiçoamento da atividade de agentes antibacterianos de oxazolidinona usando-se derivados de arginina
JP2000204084A (ja) 1998-11-11 2000-07-25 Hokuriku Seiyaku Co Ltd チオカルバミド酸誘導体
HK1040707A1 (zh) 1998-11-27 2002-06-21 法玛西雅厄普约翰美国公司 具有硫代羰基官能團的噁唑烷酮抗菌劑
US6297242B1 (en) 1999-08-12 2001-10-02 Ortho-Mcneil Pharmaceutical, Inc. N-substituted amidine and guanidine oxazolidinone antibacterials and methods of use thereof
SK7572002A3 (en) * 1999-12-21 2002-12-03 Upjohn Co Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AU5311301A (en) 2000-04-20 2001-11-07 Upjohn Co Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis
AU5889701A (en) 2000-06-05 2001-12-17 Dong A Pharm Co Ltd Novel oxazolidinone derivatives and a process for the preparation thereof
PE20020044A1 (es) * 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
AU2001272961A1 (en) 2000-06-30 2002-01-14 Pharmacia & Upjohn Company Compositions for treating bacterial infections containing oxazolidinone compound, sulbactam and an ampicillin
US6696426B2 (en) 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
PE20020578A1 (es) * 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
ES2256318T3 (es) * 2000-10-17 2006-07-16 PHARMACIA & UPJOHN COMPANY LLC Metodos de produccion de compuestos de oxazolidinona.
EP1365739A1 (en) * 2001-02-05 2003-12-03 Pharmacia & Upjohn Company Composition for rectal delivery of an oxazolidinone antibacterial drug
GB0108764D0 (en) * 2001-04-07 2001-05-30 Astrazeneca Ab Chemical compounds
JP2004521937A (ja) 2001-04-20 2004-07-22 ファルマシア・アンド・アップジョン・カンパニー オキサゾリジノンの製法
AU2002255803B2 (en) 2001-04-20 2008-07-03 Pharmacia And Upjohn Company Process to prepare oxazolidinones
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
CA2453182A1 (en) 2001-07-10 2003-01-23 Meredith L. Greene Crystalline thiazine oxazolidinones
US7049443B2 (en) 2001-07-12 2006-05-23 Pharmacia & Upjohn Company Amide-containing compound having improved solubility and method of improving the solubility of an amide-containing compound
US20030069235A1 (en) 2001-09-14 2003-04-10 J. Greg Slatter Treatment for ocular infections
JP3778425B2 (ja) 2001-10-03 2006-05-24 日立金属株式会社 表示装置に用いられる電子部品用Ａｇ合金膜および表示装置に用いられる電子部品用Ａｇ合金膜形成用スパッタリングターゲット材
BR0307103A (pt) 2002-01-24 2004-12-28 Upjohn Co Dihidrotiazina e dihidrotiopirano oxazolidinovas antimicrobianas
TW200302095A (en) 2002-01-25 2003-08-01 Upjohn Co Oxazolidinone cotherapy
MXPA04008171A (es) 2002-02-22 2004-11-26 Pharmacia Corp Formulacion oftalmica con sistema de goma.
BR0307898A (pt) * 2002-02-22 2004-12-07 Pharmacia Corp Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
CN1649866A (zh) 2002-02-28 2005-08-03 阿斯特拉曾尼卡有限公司 3－环状基－5－(含氮5－元环)甲基－噁唑烷酮衍生物及其作为抗菌药物的用途
AU2003224345A1 (en) 2002-04-30 2003-11-17 Orchid Chemicals & Pharmaceuticals Antibacterial agents
TW200403240A (en) 2002-06-28 2004-03-01 Upjohn Co Difluorothioacetamides of oxazolidinones as antibacterial agents
DE60304360T2 (de) 2002-08-12 2006-11-16 Pharmacia & Upjohn Co. Llc, Kalamazoo N-aryl-2-oxazolidinone und deren derivate
WO2004026848A1 (en) 2002-09-20 2004-04-01 Lupin Limited Oxazolidinone derivatives, process for their preperation and their use as antimycobacterial agents
JP2004203809A (ja) 2002-12-26 2004-07-22 Meiji Seika Kaisha Ltd 新規ビフェニル誘導体
US20040191326A1 (en) 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
CN1816545A (zh) 2003-07-02 2006-08-09 默克制药公司 环丙基取代的噁唑烷酮抗生素及其衍生物
US20070185132A1 (en) 2003-07-02 2007-08-09 Yasumichi Fukuda Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo
ATE471937T1 (de) 2003-07-02 2010-07-15 Merck Sharp & Dohme Cyclopropylgruppensubstituierte oxazolidinonantibiotika und derivate davon
US7047020B2 (en) 2003-07-16 2006-05-16 Qualcomm Inc. Assistance techniques for subscriber units having positioning capabilities
MXPA06002188A (es) 2003-08-25 2006-04-27 Warner Lambert Co Nuevos compuestos antimicrobianos de ariloxazolidinona.
US7265140B2 (en) 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
WO2005099353A2 (en) 2004-04-19 2005-10-27 Symed Labs Limited A novel process for the preparation of linezolid and related compounds
WO2005113520A1 (en) * 2004-05-20 2005-12-01 Pharmacia & Upjohn Company Llc Substituted 2,3,5-trifluorphenyl oxazolidinones for use as antibacterial agents
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
EP1778653A1 (en) 2004-07-28 2007-05-02 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic compounds and methods of making and using the same
PE20060619A1 (es) 2004-07-29 2006-07-11 Ferrer Int Derivados de oxazolidinona como antibacterianos
WO2006038100A1 (en) 2004-10-08 2006-04-13 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
WO2006059221A2 (en) * 2004-12-03 2006-06-08 Pharmacia & Upjohn Company Llc Topical hydro-alcoholic formulations of oxazolidinone antibacterial agents
WO2006079896A2 (en) * 2005-01-27 2006-08-03 Pharmacia & Upjohn Company Llc Stable polyol formulations of oxazolidinone antibacterial agents
WO2007023507A2 (en) 2005-06-20 2007-03-01 Wockhardt Limited Oxazolidinones bearing antimicrobial activity composition and methods of preparation
EP1745784A1 (en) 2005-06-27 2007-01-24 Ferrer Internacional, S.A. Oxazolidinone derivatives and use thereof as antibiotics
DE102005047558A1 (de) 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005048824A1 (de) 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
US20080146573A1 (en) 2006-12-04 2008-06-19 Auspex Pharmaceuticals, Inc. Preparation and utility of substituted oxzolidinones
WO2008069619A1 (en) 2006-12-08 2008-06-12 Legochem Bioscience Ltd. Novel oxazolidinone derivatives, process for preparing thereof and pharmaceutical composition containing the same
JP5455906B2 (ja) 2007-08-06 2014-03-26 ミクウルク ファーマシューティカルズ，インコーポレイテッド 細菌感染症治療のための抗微生物性オルト−フルオロフェニルオキサゾリジノン
JPWO2009157423A1 (ja) 2008-06-24 2011-12-15 財団法人乙卯研究所 縮合環を有するオキサゾリジノン誘導体
MX2011002348A (es) * 2008-09-03 2011-06-27 Pfizer Terapia de combinacion para tuberculosis.
WO2010084514A2 (en) 2009-01-02 2010-07-29 Neuland Laboratories Ltd. A process for the preparation of (5s)-(n)-[[3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide
CN101993448A (zh) 2009-08-24 2011-03-30 上海柯盟医药技术有限公司 可用于治疗传染病的抗分枝杆菌的噁唑烷酮
EP2311457A1 (en) * 2009-10-19 2011-04-20 Forschungszentrum Borstel Pharmaceutical compositions for treating infections with drug resistant mycobacteria
WO2012082992A1 (en) 2010-12-15 2012-06-21 Biovista, Inc. Compositions and methods for cancer treatment
KR101271224B1 (ko) 2011-07-05 2013-06-10 한국과학기술연구원 항균활성을 갖는 신규 이중고리를 포함하는 옥사졸리디논 유도체 및 이의 제조방법
EA202190167A1 (ru) * 2015-07-17 2021-07-30 Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. Замещенные фенилоксазолидиноны для антимикробной терапии
WO2017066964A1 (en) * 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
US11040025B2 (en) 2016-02-17 2021-06-22 The Johns Hopkins University Oxazolidinone for treatment of infections with Mycobacterium tuberculosis
ITUA20161708A1 (it) 2016-02-25 2017-08-25 Riccardo Curto Sistema di parcheggio automatizzato
WO2018170664A1 (en) * 2017-03-20 2018-09-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
GB201814487D0 (en) 2018-09-06 2018-10-24 Cycle Pharmaceuticals Ltd Cancer
WO2020147504A1 (en) 2019-01-18 2020-07-23 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents

Also Published As

Publication number Publication date
AR121598A1 (es) 2022-06-22
NZ792402A (en) 2025-09-26
JP2023507683A (ja) 2023-02-24
CA3172304A1 (en) 2021-09-23
FI4121058T3 (fi) 2026-03-27
EP4121058A1 (en) 2023-01-25
US12435077B2 (en) 2025-10-07
GEP20247641B (en) 2024-07-10
PE20230002A1 (es) 2023-01-05
AU2021239937A1 (en) 2022-10-06
CR20220472A (es) 2022-11-14
WO2021188606A1 (en) 2021-09-23
CN115605208A (zh) 2023-01-13
AU2021239937B2 (en) 2023-10-26
EP4121058B1 (en) 2026-02-18
KR102824010B1 (ko) 2025-06-20
MA59079B1 (fr) 2026-03-31
US20240208958A1 (en) 2024-06-27
KR20220156577A (ko) 2022-11-25
JP7241984B2 (ja) 2023-03-17
MX2022011431A (es) 2022-10-03
GEAP202416059A (en) 2024-02-26
IL296401A (en) 2022-11-01
TWI799814B (zh) 2023-04-21
UA130497C2 (uk) 2026-03-04
CL2022002511A1 (es) 2023-03-24
DK4121058T3 (da) 2026-03-02
WO2021184339A1 (en) 2021-09-23
LT4121058T (lt) 2026-03-25
CO2022013595A2 (es) 2023-02-16
BR112022018674A2 (pt) 2022-11-01
PH12022552495A1 (en) 2024-03-25
TW202200573A (zh) 2022-01-01

Similar Documents

Publication Publication Date Title
ECSP22073580A (es) Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano
UY39780A (es) Composición fungicida que contiene compuestos de oxadiazol
ECSP21080528A (es) Compuestos antivirales que contienen nitrilo
CL2021001042A1 (es) Nuevos compuestos antihelmínticos
MX2024002538A (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t.
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
MX385731B (es) Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas.
PE20201256A1 (es) Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
ECSP21093897A (es) Compuestos y métodos de uso de los mismos como agentes antibacterianos
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
CO2026000927A2 (es) Derivado de amida sustituido con heterociclilalquinilo, método de preparación del mismo y uso del mismo
DOP2025000235A (es) Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
BR112021025618A2 (pt) Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto
MX2019003585A (es) Derivados de tetrahidropiridina y su uso como agentes antibacterianos.
BR112017008101A2 (pt) composto, composição farmacêutica, métodos para inibir o dnae bacteriano e para tratar uma infecção, e, uso de um composto.
MX2024014106A (es) Composiciones para prevenir o tratar la fibrosis pulmonar idiopatica (ipf)
AR121582A1 (es) Composiciones antivirales y métodos de uso
AR130252A1 (es) Inhibidores enzimáticos
CO2023001204A2 (es) Composición oral sólida que comprende compuesto de carbamato y método de preparación para la misma
AR134544A1 (es) Combinaciones farmacéuticas para su uso en el tratamiento de infecciones fúngicas
CL2022001935A1 (es) Compuestos antivirales que contienen nitrilo
AR127582A1 (es) Métodos para el tratamiento del cáncer